Pemphigus Vulgaris (PV) Clinical Trials and Treatments

Pemphigus Vulgaris is an autoimmune blistering disease characterized by production of IgG autoantibodies against desmogleins, adhesion molecules essential for cell-to-cell adhesion. Antibodies target primarily desmoglein 3 (mucosal involvement) and sometimes also desmoglein 1 (mucocutaneous disease). Antibody binding disrupts cell adhesion, leading to acantholysis (loss of cell-to-cell adhesion) and intraepidermal blister formation.

The most common symptoms of Pemphigus Vulgaris include Painful blisters and erosions in mouth, often first sign, Flaccid blisters on skin that rupture easily, Painful erosions on face, scalp, chest, and genital area, Loss of appetite from oral involvement, Secondary infections of eroded areas, among others. Approximately 0.5-3.2 cases per 100,000 people; higher incidence in certain ethnic groups (Ashkenazi Jews, Mediterranean, Indian populations). Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Pemphigus Vulgaris from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. The FDA approved rituximab (Rituxan) in June 2018 for adults with moderate to severe pemphigus vulgaris. Its label pairs 2 infusions given 2 weeks apart with a tapering course of corticosteroids.

Yes. As of October 21, 2026, 1 FDA-approved medicine has a current label that names Pemphigus Vulgaris: Truxima (rituximab-abbs). Corticosteroids and immune globulins count once each.

The exact cause of Pemphigus Vulgaris is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. Autoimmune (anti-desmoglein antibodies); not inherited, though HLA-linked predisposition explains higher rates in some populations. Approximately 0.5-3.2 cases per 100,000 people; higher incidence in certain ethnic groups (Ashkenazi Jews, Mediterranean, Indian populations). Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Pemphigus Vulgaris. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. Autoimmune (anti-desmoglein antibodies); not inherited, though HLA-linked predisposition explains higher rates in some populations.

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Pemphigus Vulgaris clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Pemphigus Vulgaris clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.